To determine whether prescription patterns of hormone replacement therapy (HRT) differ in African-American, Asian, Latina, Soviet immigrant, and white women.
S
tudies suggest that the use of postmenopausal hormone replacement therapy (HRT) reduces osteoporotic fractures, [1] [2] [3] [4] [5] [6] [7] mortality from coronary heart disease (CHD), 6, 8, 9 and all-cause mortality. 8, 10, 11 It increases the risk of endometrial cancer and probably increases the risk of breast cancer. 6, [12] [13] [14] [15] A recently completed clinical trial showed no overall benefit and some increased risk among women with established CHD randomized to take HRT compared with those taking placebo. 16 The vast majority of women in these studies were white; therefore, little is known about the relation between postmenopausal estrogens and these outcomes in women of color. Similarly, most of the studies that evaluate patterns of use of HRT, physician prescribing patterns for postmenopausal estrogens, or patient or clinician attitudes on HRT either have no data on the ethnicity of the women under consideration or have focused exclusively on white women. [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] Several studies have directly compared rates of HRT use by ethnicity. Two population-based studies found higher rates of HRT use by white women in comparison with nonwhite women. 30, 31 Other population-based studies comparing HRT use among African-American and white women have found either no difference or lower rates in African Americans. [32] [33] [34] Results from studies using clinical samples suggest that African-American women are less likely than white women to be offered or to take HRT. [34] [35] [36] However, one study from a single academic clinical practice found no differences between 83 AfricanAmerican and 53 white women. 37 The only study to compare HRT use in a multiethnic sample was conducted among women physicians and found that ethnicity was not associated with personal use of HRT. 38 Several studies have evaluated the role of osteoporosis in determining HRT use and prescribing. 19, 25, 39, 40 There is much less information on how other diagnoses, such as hypertension and CHD, affect prescribing patterns for HRT. 41, 42 There are no data on the relation between patient race or ethnicity and these clinical factors in determining which women are prescribed HRT. The objectives of this study were to compare HRT prescribing patterns by race and ethnicity for women at an academic medical center, and then to assess the extent to which age, comorbid illness, and a socioeconomic indicator affected prescribing patterns. medical record system used at the University of California at San Francisco Medical Center (UCSF). The handwritten records entered by clinicians at patient visits are transcribed into the computer system. The STOR system contains information on all outpatient visits to UCSF, including the patient's medical record number, age, sex, ethnicity, ZIP code, dates and sites of clinic visits, medical problem list, and prescribed medicines. There is no information on the level of education attained by the patient. Women for whom data on race or on route of estrogen use were incomplete were excluded from the study.
The records of all women, aged 50 years and older, seen in the general internal medicine, family medicine, and gynecology practices at UCSF from January 1, 1992, to November 30, 1995 , were eligible to be selected for review. These practices have over 70,000 annual visits and follow approximately 20,000 patients. These UCSF practices attract a diverse group of adults, most of whom live or work in the city of San Francisco. Insurance coverage for adults is approximately divided into Medicare 30%, managed care plans 40%, MediCal 25%, and self-pay 5%. There are no established guidelines on use of HRT.
Definition of Variables
Hormone replacement therapy was defined as any evidence on review of medication listings that oral or transdermal noncontraceptive estrogen had been prescribed over the study period, with or without progesterone, tamoxifen, or vaginal estrogen. Topical estrogen use was analyzed separately. Women whose only prescribed estrogen was tamoxifen or vaginal estrogen were not considered to be on HRT. There were no data on adherence to the prescribed medication.
The main predictor variable was self-identified patient ethnicity collected at the time of patient registration. Responses were classified as African American, Asian, Latina, white, Soviet immigrant, "other," or "unknown," in mutually exclusive categories. In the UCSF database, Soviet immigrants were placed in a separate ethnic category for administrative purposes. This category was maintained distinct from other white women for this analysis because of anecdotal evidence that Soviet immigrants were reluctant to take HRT. Women identified as of other or unknown ethnicity were excluded.
Age was defined by age at first visit in the study period. Clinical diagnoses obtained from the computerized medical record included hypertension, diabetes mellitus, CHD, osteoporosis, or breast cancer. Reliable data on hysterectomy status and cholesterol levels were not available for all women.
The median household income for the ZIP code of patient residence obtained from the 1990 U.S. Census was used to indicate socioeconomic status. This measure has been used to evaluate the socioeconomic status of individual patients when using administrative data sets. 43, 44 
Validation of Computerized Records
Two physicians blinded to race or ethnicity of the patients reviewed charts of a stratified random sample of 150 estrogen users and nonusers to evaluate agreement between the computerized data and the medical record. Kappa statistics were obtained to assess concordance on estrogen use, progesterone use, ethnicity, and disease states. In addition, we compared agreement on estrogen use by ethnicity.
Data Analysis
Summary statistics for all demographic and clinical variables were computed separately by ethnic group. Bivariate associations between white patients and other ethnic groups were assessed using analysis of variance procedures for continuous variables and 2 analysis for categorical variables. In addition, each ethnic group was divided into two age groups, those aged 65 years or less, and those older. To adjust for multiple comparisons in this analysis, the value for statistical significance in univariate comparisons was set at p ϭ .01. Multivariate analyses of the demographic and clinical variables were conducted using logistic regression models to calculate odds of prescribing HRT within 95% confidence limits for each ethnic group using whites as the reference group. Predictor variables in the model were age (5-year intervals), median income by ZIP code of residence, and clinical diagnoses.
RESULTS
Over the 35-month study period, 10,276 women aged 50 years or older were seen in the general internal medicine, family medicine, and gynecology practices at UCSF. We excluded 753 women classified as "other race," 303 women for whom no ethnicity was coded, and 252 women for whom no route of administration of estrogen was listed, leaving 8,968 study subjects. Of these, 4,492 (50.0%) were white; 1,819 (20.2%), Asian; 1,319 (14.7%), African American; 774 (8.6%), Latina; and 564 (6.3%), Soviet immigrant.
Demographic and clinical characteristics of the study population are shown in Table 1 . Mean age was similar by race and ethnicity, but African-American, Asian, and Soviet immigrant women had significantly lower median incomes than white women. African Americans were more likely than whites to have hypertension, diabetes, and CHD, but less likely to have osteoporosis. Compared with whites, Asians were significantly more likely to be diagnosed with hypertension and diabetes, while Latinas were more likely to have hypertension. Soviet immigrants were significantly more likely than whites to have hypertension and diabetes, and less likely than whites to have osteoporosis. There were no significant differences in breast cancer diagnoses across ethnic groups.
Chart Review Validation
There was a high level of agreement between the STOR system and review of a random sample of the 300 written charts for having estrogen on the medication list ( ϭ 0.82; 95% CI 0.73, 0.91) or for having a progesterone prescription documented ( ϭ 0.87; 95% CI 0.79, 0.95). In addition, there were no significant differences in agreement by ethnicity. For the five ethnic categories, there was good concordance between the STOR system and the medical chart ( ϭ 0.75; 95% CI 0.63, 0.87). For diabetes ( ϭ 0.71; 95% CI 0.55, 0.87) and hypertension ( ϭ 0.67; 95% CI 0.56, 0.78), there was good agreement between the STOR system and chart review diagnoses. However, agreement was poorer for CHD ( ϭ 0.52; 95% CI 0.30, 0.74) and osteoporosis ( ϭ 0.53; 95% CI 0.29, 0.77).
Hormone Replacement Therapy Prescribing Patterns
White women were more likely than all others to be prescribed estrogens, with 33.1% on HRT (Table 2 ). Only 6.6% of Soviet immigrants received HRT, significantly less than the proportion of women from the other ethnic groups studied. All other ethnic groups were less likely than whites to be prescribed oral or transdermal estrogen with progesterone. For vaginal estrogens, only Latinas had significantly different rates of use from whites.
Stratification by age showed that women over 65 years of age were half as likely as those between 50 and 65 years of age to be on HRT (35.6% vs 18.0%). The differences in the proportion of white women and women of other ethnic groups on HRT were greater among those over 65 years of age. White women had higher rates of HRT use than other women within both age groups, but this difference was not statistically significant in AfricanAmerican women in the age group between 50 and 65 years (41.4% vs 36.5%, p ϭ .05; significance set at p Ͻ .01).
Multivariate Analyses
Multivariate analysis showed statistically significant differences in HRT prescribing patterns between white women and women of other ethnic groups even after adjusting for age, median income, diabetes, hypertension, CHD, and osteoporosis. In comparison with white women, all other groups of women were less likely to be prescribed HRT, with the adjusted odds relative to whites for Asians, African Americans, Latinas, and Soviet immigrants all statistically significant at p Ͻ .01 (Table 3) . Osteoporosis was independently associated with higher odds of HRT prescribing (OR 2.26; 95% CI 1.71, 2.99), and the presence of hypertension was associated with lower odds of HRT prescribing (OR 0.76; 95% CI 0.68, 0.85). There was no association between estrogen prescribing and CHD (OR 0.86; 95% CI 0.68, 1.09), and a borderline increase in the odds of HRT in women with a diagnosis of diabetes (OR 1.18; 95% CI 1.00, 1.40). A diagnosis of breast cancer was not included in the logistic model because only 1 of the 75 women with breast cancer was prescribed HRT. For HRT use by women with breast cancer, the unadjusted OR was 0.04 (99% CI 0.000, 0.485).
DISCUSSION
Our study shows that white women over 50 years old in these academic practice settings are more likely than women of other ethnic categories to be prescribed noncontraceptive estrogens. This disparity is greatest in older women and persists even after adjusting for the available demographic and clinical factors that may influence HRT prescribing. Furthermore, we found that CHD was not associated with increased odds of HRT use even though at the time of this study there was increasing consensus that this is likely to be the setting in which HRT may be of greatest benefit. Lack of benefit of HRT in secondary prevention is now likely to diminish the enthusiasm with which physicians recommend treatment in women at risk of CHD. 16 However, lack of efficacy in CHD outcome does not invalidate our finding that prescribing patterns differ by the patient race or ethnicity and the need to address factors that underlie these differences.
Recommendations on the clinical indications for HRT use have changed over the past 20 years, 17 with the most persuasive data indicating that the greatest reduction in morbidity and mortality from use of HRT results from reductions in coronary disease. 9 Observations of benefit of HRT on CHD outcomes have to be reconsidered as potentially confounded in view of one randomized clinical trial showing no benefit despite adequate power. 16 Most studies evaluating women's attitudes on HRT have focused on osteoporosis benefit and uterine and breast cancer risk. 24, 25, 27, 29, 39 One study on attitudes toward HRT and cardiovascular risk showed that although women may believe that HRT will decrease the risk of heart disease, they also underestimate their risk of heart disease relative to osteoporosis. Furthermore, women fear potential longterm risks of HRT such as breast cancer more than they fear CHD. 28 Studies evaluating clinicians' knowledge of indications for HRT use have emphasized osteoporosis risk and menopausal symptoms, 25, 27, 39, 40, 45, 46 but infrequently addressed CHD risk. 28 Thus, while clinicians report a willingness to prescribe HRT for women at risk of osteoporosis or with menopausal symptoms, they are less willing to prescribe HRT for women with CHD or CHD risk factors. 30, 42 For example, despite evidence showing no adverse effect and potentially a beneficial effect of HRT on systolic blood pressure, a survey of British physicians found reluctance to prescribe HRT to postmenopausal women with hypertension. 42 Although we did not have information on menopausal symptoms, our findings suggest that osteoporosis risk is a more influential factor in the decision to prescribe HRT than known CHD risk factors. This finding has particular significance for AfricanAmerican women and highlights a serious limitation of the HRT research to date.
African-American women are disproportionately affected by CHD and have rates of coronary mortality over 30% higher than in white women. 47 Given this high risk of CHD, African-American women may benefit more in absolute terms from HRT than do white women. However, some studies show that the postmenopausal rise in total cholesterol level seen in whites does not occur in African Americans, suggesting that one of the mechanisms by which postmenopausal HRT may act does not have the same impact in African-American women. 48, 49 There have been more than 30 observational studies to assess the effect of postmenopausal estrogen on CHD, the majority of which show a protective effect of HRT. 6, 9 However, most of these studies included only white women, did not indicate the racial or ethnic category of the study participants, or had insufficient numbers of nonwhite patients to perform separate analyses of outcomes such as sudden death, myocardial infarction, or extent of stenosis. 50 Furthermore, there are no published randomized trials evaluating the efficacy of HRT in primary prevention of CHD morbidity and mortality. Similarly, nearly 90% of randomized participants in the HERS trial were white, and possible biological differences in response to HRT by race or ethnicity were not possible to address. 16 Although racial and ethnic differences were striking in our study, we found higher overall rates of HRT prescribing for white and African-American women than most other studies. In the nonblack, community-based Study of Osteoporotic Fractures, 17.7% of women used HRT, 18 while 31% of the women in a white cohort in Rancho Bernardo, Calif, used postmenopausal estrogens. 20 The highest reported rates of use were among women physicians, 47.4% of whom were current users of HRT, with no significant differences by race or ethnicity. 38 In the Atherosclerotic Risk in Communities study, white women had a 22% rate of HRT use compared with 18% for African-American women. 51 An earlier populationbased study of middle-aged women conducted in Pittsburgh, Pa, found that only 6.1% of whites and 3.4% of African Americans used HRT, a significant difference that persisted after adjusting for confounding variables. 33 Analyses of the National Ambulatory Medical Care Survey showed similarly low rates of HRT prescribing, with white women receiving HRT in 7% of office visits compared with 4% for nonwhites. 30 Bartman and Moy reported analyses of the 1987 National Health Interview Survey and found that African-American women compared with white women had an adjusted OR of 0.38 (95% CI 0.24, 0.61) of ever having used estrogen in the past. 34 Analyses of the 1987 National Medical Expenditure Survey showed that African-American women were 50% less likely to receive a prescription for estrogen. 34 Women who smoked, lived in the Northeast, or were poor or had a low income were also less likely to receive an estrogen prescription in 1987. 34 Finally, a study of 141 patients in a primary care clinic in New Haven from 1993 found that 15.7% of African Americans and 5.7% of white women were current users of HRT. 37 A recently published survey of postmenopausal women drawn from a probability sample of U.S. households reported that 37.6% of these women currently use HRT. 31 Although only 11% of the respondents were nonwhite, these women were less likely to report HRT use independent of having had a hysterectomy. In multivariate models, ethnicity was not a significant predictor of HRT use. 31 Having had a hysterectomy, having a college degree, calcium use, and concern about attractiveness were associated with 2-to 5-fold increased odds of HRT use, but increasing age, diabetes, and lack of a regular physician significantly decreased odds of HRT use. 31 Women living in the West were more likely to report current HRT use, and the rate observed was similar to that for white women in our study. Other cardiovascular risk factors had no effect on current use of HRT.
Ethnic differences in health status and in the utilization of health care services in the United States are most often ascribed to socioeconomic factors, but cultural factors affecting patient-clinician communication may also play an important role. The large disparity in HRT use between Soviet immigrants and the other white women in our study may reflect cultural differences or communication difficulties due to language and translation. 52 For some of the Asian and Latina women in this study, cultural and language factors may also play a significant role in deciding on HRT use, but were not possible to address with our design.
There are several limitations of this study. First, the analyses are confined to the practices at one academic medical center, limiting the generalizability of the findings. Second, because the STOR system at best captures only what clinicians document, we may be missing data on estrogen use and other clinical information for certain patients, or there may be errors made by transcribers in coding written diagnoses or therapies. However, these types of misclassification errors would dilute the strength of our findings and bias the results toward the null. Further, there is no reason to believe that there is differential omission or miscoding of data by race or ethnicity. Moreover, our chart reviews showed generally good agreement between the medical record and the STOR system, with no differences by race or ethnicity that would account for the ethnic or racial differences we observed. Third, because this is a retrospective review, we had no information on variables that may affect the decision to use HRT such as the education level of patients, 31, 53 menopausal symptoms or hysterectomy status, and lipid levels. Ethnic differences in rates of hysterectomy may explain the lower levels of combined estrogen and progestin use in all other groups compared with whites, but are unlikely to account for the entire difference in HRT prescribing patterns between these groups of women. 54 Finally, although our study shows differences in HRT prescribing patterns, it was not designed to assess the specific roles that physician recommendations or patient preferences play in the observed prescription patterns, nor did we have data on actual adherence to prescribed estrogens.
Despite these limitations, the observed differences in HRT prescribing patterns by race or ethnicity merit further investigation. Future research should evaluate patient preferences regarding HRT as a function of ethnicity and socioeconomic status, analyze the role that patient ethnicity has in physician recommendations regarding HRT use, and examine whether the competing risks and benefits of HRT use differ by ethnicity. There is considerable uncertainty about the risks and benefits of HRT among patients even in the setting of persuasive scientific evidence. 55 Our data show that nonwhite women and recent immigrants are less likely to use HRT and that CHD risk is not an important determinant of prescribing patterns (probably correctly so with current information). Both clinicians and patients will most likely remain uncertain about the appropriateness of HRT in different populations until research clarifies risks and benefits for all women and explores the potential for cultural differences in attitudes toward the use of HRT.
